NCT03455556 is a Phase 1 clinical trial of Anetumab Ravtansine in Mesothelin Positive, sponsored by Mayo Clinic.

Who is sponsoring NCT03455556?

NCT03455556 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03455556?

Interventions in NCT03455556: Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis.

What condition does NCT03455556 study?

NCT03455556 studies Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7.

Is NCT03455556 still recruiting?

NCT03455556 is currently terminated. Last updated 6 January 2023.

Are results published for NCT03455556?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-01-06 · How we verify

NCT03455556

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Terminated Phase 1 Results posted Last updated 6 January 2023

What this trial tests

Phase 1 trial testing Anetumab Ravtansine in Mesothelin Positive in 1 participant. Terminated before completion.

Timeline

10 August 2018

Primary endpoint
11 September 2019

7 January 2020

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	10 August 2018
Primary completion	11 September 2019
Estimated completion	7 January 2020
Sites	3 locations across United States

Drugs / interventions tested

Anetumab Ravtansine — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →
Laboratory Biomarker Analysis — full drug profile →

Conditions studied

Mesothelin Positive — all drugs for Mesothelin Positive →
Stage III Non-Small Cell Lung Cancer AJCC v7 — all drugs for Stage III Non-Small Cell Lung Cancer AJCC v7 →
Stage IIIA Non-Small Cell Lung Cancer AJCC v7 — all drugs for Stage IIIA Non-Small Cell Lung Cancer AJCC v7 →
Stage IIIB Non-Small Cell Lung Cancer AJCC v7 — all drugs for Stage IIIB Non-Small Cell Lung Cancer AJCC v7 →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Mesothelin Positive or Stage III Non-Small Cell Lung Cancer AJCC v7. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other places in the body. Monoclonal antibodies, such as anetumab ravtansine and atezolizumab, may interfere with the ability of tumor cells to grow and spread.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R, Blumenschein GR, Moore KN, Santin AD, et al · · 2020 · cited 136× · PMID 32213105 · DOI 10.1200/jco.19.02085
Mesothelin as a biomarker for targeted therapy.
Lv J, Li P, Li P. · · 2019 · cited 101× · PMID 31463062 · DOI 10.1186/s40364-019-0169-8
Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H. · · 2020 · cited 95× · PMID 32111076 · DOI 10.3390/biom10030360
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, et al · · 2020 · cited 78× · PMID 33322522 · DOI 10.3390/cancers12123729
Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer Activity.
Zhang D, Kanakkanthara A. · · 2020 · cited 48× · PMID 32610496 · DOI 10.3390/cancers12071721
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
Abuhelwa Z, Alloghbi A, Nagasaka M. · · 2022 · cited 42× · PMID 35472631 · DOI 10.1016/j.ctrv.2022.102393
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Zhou L, Lu Y, Liu W, Wang S, et al · · 2024 · cited 27× · PMID 38429828 · DOI 10.1186/s40164-024-00493-8
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
Montemagno C, Cassim S, Pouyssegur J, Broisat A, et al · · 2020 · cited 25× · PMID 32517181 · DOI 10.3390/ijms21114067

Verify or expand the search:

Other trials of Anetumab Ravtansine

Trials testing the same drug.

NCT03816358 — Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivol · Phase 1 · active not recruiting
NCT03587311 — Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Prima · Phase 2 · active not recruiting
NCT03126630 — Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma · Phase 1, PHASE2 · active not recruiting
NCT02839681 — Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma · Phase 2 · terminated

Other recruiting trials for Mesothelin Positive

Currently open trials in the same condition.

NCT06623396 — A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer · Phase 1 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03455556 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 6 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03455556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing